A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.Consistent with the reports the panobinostat/ruxolitinib combination demonstrated the anticipated AEs but was considered tolerable in a small number of patients as showcased by those experiencing clinical benefits after ≥5 years of treatment

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis / Harrison, Claire; Heidel, Florian H; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Hayat, Amjad; Passamonti, Francesco; Conneally, Eibhlin; Kindler, Thomas; Martino, Bruno; Lipka, Daniel B; Stefanelli, Tommaso; Roussou, Pantelia; Germano, Davide; Ewan, Jacqueline; Ribrag, Vincent. - In: HEMASPHERE. - ISSN 2572-9241. - ELETTRONICO. - 6:(2022), pp. 1-4. [10.1097/HS9.0000000000000757]

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Vannucchi, Alessandro M
Writing – Original Draft Preparation
;
2022

Abstract

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.Consistent with the reports the panobinostat/ruxolitinib combination demonstrated the anticipated AEs but was considered tolerable in a small number of patients as showcased by those experiencing clinical benefits after ≥5 years of treatment
2022
6
1
4
Harrison, Claire; Heidel, Florian H; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Hayat, Amjad; Passamonti, Francesco; Conneally, Eibhlin; Kindler, Thomas; Martino, Bruno; Lipka, Daniel B; Stefanelli, Tommaso; Roussou, Pantelia; Germano, Davide; Ewan, Jacqueline; Ribrag, Vincent
File in questo prodotto:
File Dimensione Formato  
hs9-6-e757.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 359.25 kB
Formato Adobe PDF
359.25 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1286996
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact